医学
重症肌无力
上睑下垂
眼肌无力
复视
皮质类固醇
甲基强的松龙
强的松
斜视
不利影响
外科
肌痛
内科学
作者
Yoon Gon Lee,Ungsoo Kim
出处
期刊:Journal of Pediatric Ophthalmology & Strabismus
[SLACK, Inc.]
日期:2018-09-20
卷期号:55 (5): 339-342
被引量:14
标识
DOI:10.3928/01913913-20180620-01
摘要
Purpose: To evaluate the response to corticosteroid therapy as a primary treatment for ocular myasthenia gravis. Methods: Patients diagnosed as having ocular myasthenia gravis by an acetylcholine receptor binding antibody test between January 2011 and September 2015 were included in the study and started receiving treatment with a corticosteroid. Patients with a blowout fracture, hyperthyroidism, diabetes mellitus, hypertension, cardiovascular disease, or history of strabismus surgery were excluded. Disappearance of diplopia and ptosis were considered a response to treatment. Results: Methylprednisolone therapy was administered to 29 patients (19 men and 10 women; average age: 49 ± 16.5 years) as an initial treatment. A total of 6 patients were lost to follow-up. Twenty-three of 29 patients (82.6%) were regarded as having presented a response to treatment. The average treatment duration was 3 weeks for patients responding to primary treatment. Eight patients complained of adverse effects from steroid therapy such as heartburn, insomnia, weight gain, and myalgia. Conclusions: A corticosteroid could be considered as an initial treatment for patients diagnosed as having ocular myasthenia gravis by an acetylcholine receptor binding antibody test. [ J Pediatr Ophthalmol Strabismus . 2018;55(5):339-342.]
科研通智能强力驱动
Strongly Powered by AbleSci AI